according story houston chronicle case first lilly assuaging investor fears zyprexa sales would decline successful trial iloperidone caused following according chronicle shares vanda pharmaceuticals inc soared new week high rockville md based biotech drug maker reported early thursday schizophrenia treatment iloperidone effective late stage clinical trial vanda shares jumped percent afternoon trading times average volume shares reached new year high earlier session traded past weeks wyeth lundbeck bifeprunox wednesday drug makers wyeth solvay pharmaceuticals inc lundbeck said studies schizophrenia treatment bifeprunox showed patients scored better symptom tests also battled common side effect weight gain one study showed patients taking bifeprunox lost average pounds six weeks given placebo lost average pounds directly comparable companies noted small subgroups patients given current antipsychotic drugs validate study placebo gained average pounds pounds six weeks little bit background information needed put exciting bits science context far bifeprunox goes pharmagossip pointed back drug taking long time hit market see another brief clipping delay delays often mean drug effective manufacturer hoped iloperidone one article forecasted would hit market digging indicated titan holds license iloperidone extent anyway spot trouble allegedly hiding drug side effect profile according report filed company funds necessary complete clinical development iloperidone currently pursuing several financing alternatives including corporate partnering arrangements balance sheet financing complete development iloperidone i assume vanda got involved i could find single published trial ilopderidone either pubmed clinicaltrials gov anybody direct me clinical trials data product i love see drug clinical trials phase development nearly decade published data show efficacy i impressed personal opinion better burning money investing vanda huge jump earlier week